320 related articles for article (PubMed ID: 28419441)
21. Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
Mikhailova E; Semchenkova A; Illarionova O; Kashpor S; Brilliantova V; Zakharova E; Zerkalenkova E; Zangrando A; Bocharova N; Shelikhova L; Diakonova Y; Zhogov V; Khismatullina R; Molostova O; Buldini B; Raykina E; Larin S; Olshanskaya Y; Miakova N; Novichkova G; Maschan M; Popov AM
Br J Haematol; 2021 May; 193(3):602-612. PubMed ID: 33715150
[TBL] [Abstract][Full Text] [Related]
22. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.
Patkar N; Alex AA; B B; Ahmed R; Abraham A; George B; Vishwabandya A; Srivastava A; Mathews V
Cytometry B Clin Cytom; 2012 Jul; 82(4):252-8. PubMed ID: 22467604
[TBL] [Abstract][Full Text] [Related]
23. Application and prognostic relevance of CD34 detection in immunophenotyping of pediatric acute B lymphoblastic leukemia.
Zha W; Yuan Y; Yang T; Zhu LJ; Kong WY; Zhuo JJ
Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3384-3390. PubMed ID: 38766795
[TBL] [Abstract][Full Text] [Related]
24. Detection of Minimal Residual Disease in B Cell Acute Lymphoblastic Leukemia Using an Eight-Color Tube with Dried Antibody Reagents.
Bouriche L; Bernot D; Nivaggioni V; Arnoux I; Loosveld M
Cytometry B Clin Cytom; 2019 Mar; 96(2):158-163. PubMed ID: 30698327
[TBL] [Abstract][Full Text] [Related]
25. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?
Sędek Ł; Bulsa J; Sonsala A; Twardoch M; Wieczorek M; Malinowska I; Derwich K; Niedźwiecki M; Sobol-Milejska G; Kowalczyk JR; Mazur B; Szczepański T
Cytometry B Clin Cytom; 2014 Sep; 86(5):329-39. PubMed ID: 24845957
[TBL] [Abstract][Full Text] [Related]
26. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
27. Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.
Thulasi Raman R; Anurekha M; Lakshman V; Balasubramaniam R; Ramya U; Revathi R
Leuk Lymphoma; 2020 Aug; 61(8):1974-1980. PubMed ID: 32281503
[TBL] [Abstract][Full Text] [Related]
28. The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia.
Wang W; Gao L; Li Y; Li ZL; Gong M; Huang FZ; Chen YR; Zhang CX; Gao YY; Ma YG
Leuk Lymphoma; 2016 May; 57(5):1174-81. PubMed ID: 26436205
[TBL] [Abstract][Full Text] [Related]
29. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.
Theunissen P; Mejstrikova E; Sedek L; van der Sluijs-Gelling AJ; Gaipa G; Bartels M; Sobral da Costa E; Kotrová M; Novakova M; Sonneveld E; Buracchi C; Bonaccorso P; Oliveira E; Te Marvelde JG; Szczepanski T; Lhermitte L; Hrusak O; Lecrevisse Q; Grigore GE; Froňková E; Trka J; Brüggemann M; Orfao A; van Dongen JJ; van der Velden VH;
Blood; 2017 Jan; 129(3):347-357. PubMed ID: 27903527
[TBL] [Abstract][Full Text] [Related]
30. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
[TBL] [Abstract][Full Text] [Related]
31. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease.
van Wering ER; van der Linden-Schrever BE; Szczepański T; Willemse MJ; Baars EA; van Wijngaarde-Schmitz HM; Kamps WA; van Dongen JJ
Br J Haematol; 2000 Jul; 110(1):139-46. PubMed ID: 10930991
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract][Full Text] [Related]
33. The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease.
Hsu FC; Hudson C; Wilson ER; Pardo LM; Singleton TP; Xu D; Zehentner BK; Hitzler J; Berman J; Wells DA; Loken MR; Brodersen LE
Cytometry B Clin Cytom; 2023 Jul; 104(4):311-318. PubMed ID: 37015883
[TBL] [Abstract][Full Text] [Related]
34. Initial frequency of CD34+/CD38 - cells is not correlated with minimal residual disease level in 73 Chinese children with B-cell precursor acute lymphoblastic leukemia.
Feng JH; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Xu WQ
Leuk Lymphoma; 2013 Sep; 54(9):2073-5. PubMed ID: 23323948
[No Abstract] [Full Text] [Related]
35. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
[TBL] [Abstract][Full Text] [Related]
36. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
37. Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors.
Reis-Alves SC; Traina F; Metze K; Lorand-Metze I
Diagn Pathol; 2015 Apr; 10():44. PubMed ID: 25924846
[TBL] [Abstract][Full Text] [Related]
38. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection.
Weir EG; Cowan K; LeBeau P; Borowitz MJ
Leukemia; 1999 Apr; 13(4):558-67. PubMed ID: 10214862
[TBL] [Abstract][Full Text] [Related]
39. [Proportions of cells expressing CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, or CD13,33+/CD34+ in the regenerating bone marrows during complete remission of acute leukemia or after bone marrow transplantation].
Kahng J; Shin SY; Han K
Korean J Lab Med; 2007 Dec; 27(6):406-13. PubMed ID: 18160830
[TBL] [Abstract][Full Text] [Related]
40. The role of multiparametric flow cytometry in the detection of minimal residual disease in acute leukaemia.
Lee D; Grigoriadis G; Westerman D
Pathology; 2015 Dec; 47(7):609-21. PubMed ID: 26517623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
